Market Overview - The diversified financial sector experienced a decline of 2.57% on January 15, with Lakala leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable performers in the diversified financial sector included: - Sichuan Shuangma (Code: 000935) with a closing price of 27.97, up 1.75% and a trading volume of 74,200 shares [1] - Bohai Leasing (Code: 000415) closed at 4.05, up 0.75% with a trading volume of 993,700 shares [1] - Jiuding Investment (Code: 600053) closed at 21.00, up 0.67% with a trading volume of 87,000 shares [1] - Conversely, Lakala (Code: 300773) saw a significant drop of 5.92%, closing at 30.18 with a trading volume of 1,582,000 shares and a transaction value of 4.804 billion [2] Capital Flow Analysis - The diversified financial sector saw a net outflow of 1.764 billion from institutional investors, while retail investors experienced a net inflow of 1.092 billion [2] - The capital flow for individual stocks showed: - Bohai Leasing had a net inflow of 41.08 million from institutional investors, but a net outflow of 33.48 million from retail investors [3] - Jiuding Investment had a net inflow of 17.84 million from institutional investors, with a net outflow of 14.78 million from retail investors [3] - Sichuan Shuangma had a net inflow of 4.18 million from institutional investors, but a net outflow of 589.49 thousand from retail investors [3]

格隆汇1月15日丨越秀资本(000987.SZ)在投资者互动平台表示，中科宇航、微纳星空、航天飞鸿为公司 控股子公司越秀产业基金管理基金的投资项目，根据商业条款，公司不便透露具体投资信息。该投资预 计不会对公司经营业绩产生重大影响。 ...

债券代码:149352 债券简称:21 越控 01 广州越秀金融控股集团股份有限公司 2021 年面向专业投资者公开发行公司债券(第一期) 2026 年本息兑付暨摘牌公告 本公司及其董事、高级管理人员保证公告内容真实、准确和完整,并对公告 中的虚假记载、误导性陈述或者重大遗漏承担责任。 特别提示 1、债券名称:广州越秀金融控股集团股份有限公司 2021 年面向专业投资 者公开发行公司债券(第一期)(以下简称"本期债券"）。 2、债券简称:21 越控 01。 3、债券代码:149352。 4、债权登记目及最后交易日:2026年1月16日。 5、本息支付日及摘牌日:2026年1月19日。 6、计息期间:2025年1月19日-2026年1月18日。 广州越秀金融控股集团股份有限公司 2021 年面向专业投资者公开发行公 司债券（第一期）将于 2026年１月 19 日支付自 2025 年 1 月 19 日到 2026 年 1 月 18 日期间的利息并支付本金,为保证还本付息工作的顺利进行,方便投资 者及时领取本金及利息,现将有关事宜公告如下: 一、本期债券的基本情况 1、发行人:广州越秀资本控股集团股份有限公司(曾用 ...

越秀资本今日下跌3.58%，全天换手率6.38%，成交额34.60亿元，振幅16.60%。龙虎榜数据显示，机构 净买入7008.32万元，深股通净卖出573.08万元，营业部席位合计净卖出1.91亿元。 深交所公开信息显示，当日该股因日振幅值达16.60%上榜，机构专用席位净买入7008.32万元，深股通 净卖出573.08万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交8.14亿元，其中，买入成交额为3.44亿 元，卖出成交额为4.70亿元，合计净卖出1.26亿元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买三、买四、买五，合计买入金额 1.48亿元，卖出金额7825.99万元，合计净买入7008.32万元，深股通为第一大买入营业部及第二大卖出 营业部，买入金额为8721.01万元，卖出金额为9294.09万元，合计净卖出573.08万元。 卖五 华泰证券股份有限公司成都蜀金路证券营业部 162.34 3688.32 （文章来源：证券时报网） 资金流向方面，今日该股主力资金净流出2.14亿元，其中，特大单净流出2.31亿元，大单资金净流入 1747.26万元。近5日主力资金 ...

证券之星消息，1月14日多元金融板块较上一交易日上涨1.43%，拉卡拉领涨。当日上证指数报收于 4126.09，下跌0.31%。深证成指报收于14248.6，上涨0.56%。多元金融板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002316 | 亚联发展 | 5.36 | -5.13% | 112.34万 | 6.04亿 | | 000987 | 越秀资本 | 10.22 | -3.58% | 319.84万 | 34.60亿 | | 600901 | 江苏金相 | 6.17 | -1.75% | 40.59万 | 2.52亿 | | 665009 | *ST能猫 | 8.59 | -1.49% | 5.86万 | 5024.64万 | | 000415 | 渤海相信 | 4.02 | -1.47% | 105.13万 | 4.29 乙 | | 000935 | 四川双马 | 27.49 | -1.29% | 13.79万 | 3.84亿 | | 600053 | 九鼎投 ...

Group 1 - The core viewpoint of the news is that Yuexiu Capital has seen a stock price increase of 5.28%, reaching 11.16 CNY per share, with a trading volume of 797 million CNY and a turnover rate of 1.49%, resulting in a total market capitalization of 55.991 billion CNY [1] - Yuexiu Capital, established on December 24, 1992, and listed on July 18, 2000, is based in Guangzhou, Guangdong Province, and its main business areas include distressed asset management, financial leasing, private equity fund management, and capital investment [1] - The revenue composition of Yuexiu Capital is as follows: 43.40% from new energy business, 27.16% from futures business, 23.26% from financial leasing, 4.65% from distressed asset management, and 1.53% from investment management [1] Group 2 - From the perspective of major fund holdings, Guolian Fund has one fund heavily invested in Yuexiu Capital, specifically Guolian Jingsheng One-Year Holding Mixed A (011353), which held 55,700 shares, accounting for 0.28% of the fund's net value, making it the second-largest holding [2] - The Guolian Jingsheng One-Year Holding Mixed A fund was established on May 14, 2021, with a current scale of 144 million CNY, and has achieved a year-to-date return of 1.01%, ranking 7059 out of 8838 in its category [2] - The fund managers of Guolian Jingsheng One-Year Holding Mixed A include Chen Xinyu, with a tenure of 6 years and 169 days, and a best return of 82.83% during his tenure; Huo Shunchao, with a tenure of 2 years and 281 days, and a best return of 26.96%; and Ye Tianyang, with a tenure of 281 days, and a best return of 14.74% [2]

Group 1 - The core viewpoint of the article is that Yuexiu Capital is focusing on investment in sectors aligned with national strategic development, particularly in defense technology and commercial aerospace [2] - Yuexiu Capital's subsidiary, Yuexiu Industrial Fund, has established a commercial aerospace fund to invest in the aerospace industry chain [2] - The fund has invested in several quality projects such as China Aerospace Science and Technology Corporation, Aerospace Feihong, and Micro-Nano Star, contributing to the development of the national aerospace industry [2] Group 2 - The investment is not expected to have a significant impact on the company's operating performance [2]

2026年1月9日，深交所主板上市公司越秀资本（000987.SZ）发布的公告显示，该公司董事长王恕慧先生因工作变动，辞去公司董事长、法定代表 人、董事及董事会专门委员会委员等职务及公司控股子公司相关职务。辞职后，王恕慧先生将不再担任公司及控股子公司任何职务。 值得关注的是，紧接着在1月12日，他还辞去了中信证券非执行董事的职务。这表示，一位身兼两家上市公司职务的金融高管，几乎同一时间于 这两家公司卸任。 早期职业：曾任原广州证券证券发行咨询部业务经理、研究拓展部副经理、董事会秘书、副总裁。 越秀集团任职：此后加入越秀集团，曾任广州越秀集团办公室总经理、发展部总经理，香港越秀总经理助理、董事、副总经理。 越秀资本体系任职：后任越秀资本党委书记、董事长，广州越秀资本控股集团有限公司董事长，广州越秀产业投资有限公司董事长，广州越秀产 业投资基金管理股份有限公司董事。 | 姓名 | 离任职务 | 离任时间 | 原定任期到 | 离任原因 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | | | | | 期日 | | ...

Core Viewpoint - Guangzhou Yuexiu Capital Holdings Group Co., Ltd. has announced the resignation of Chairman Wang Shuhui and the election of Li Feng as the new Chairman, along with the appointment of several senior management personnel [6][8]. Group 1: Board Meeting and Resolutions - The 32nd meeting of the 10th Board of Directors was held on January 12, 2026, with all 11 directors present, and the meeting complied with relevant regulations [1]. - The board unanimously approved the election of Li Feng as the new Chairman, following the resignation of Wang Shuhui due to work changes [2][6]. - Wang Shuhui's resignation was effective immediately upon delivery of his resignation report, and he will no longer hold any positions within the company or its subsidiaries [6][8]. Group 2: Appointment of Senior Management - The board approved the appointment of Lin Ying as Vice General Manager and Chief Financial Officer, and Pu Shangquan as Vice General Manager [3][6]. - The terms for the newly appointed senior management personnel will last until the end of the current board's term [3][6]. - The appointments did not result in the number of directors who are also senior management exceeding half of the total number of directors [3][6]. Group 3: Background of New Appointees - Li Feng has extensive experience in various leadership roles within the Yuexiu Group and currently holds multiple positions within the company [10][11]. - Lin Ying has a strong background in finance and management, previously serving in senior roles at PwC and within the Yuexiu Group [14][15]. - Pu Shangquan has held significant positions in banking and risk management, contributing to his current role within the company [16][17].

Core Viewpoint - Ruipai Pet Hospital Management Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become the first publicly listed pet medical company in China, marking a significant shift from "wild growth" to "standardized capitalization" in the pet medical industry [1][2] Industry Capitalization Acceleration - The pet medical industry is transitioning to a new phase of "standardized capitalization," with Ruipai's IPO seen as a pivotal moment that could establish valuation standards and operational benchmarks for the industry [2][3] - Founded in 2012, Ruipai is the first nationwide chain pet medical service provider in China, operating 548 hospitals as of June 30, 2025, and holding a 4.8% market share in the pet medical sector by revenue [2][3] Financial Performance - Ruipai's revenue grew from 1.455 billion yuan in 2022 to 1.585 billion yuan in 2023, and is projected to reach 1.758 billion yuan in 2024, with gross profit also increasing annually [3][4] - The company achieved a net profit of 15.5 million yuan in the first half of 2025, marking a turnaround from previous losses [4][5] Growth Challenges - Despite rapid growth through acquisitions, Ruipai faces challenges such as short-term profitability pressures and insufficient growth momentum, necessitating a transformation of its expansion model [1][6] - The company has experienced a significant reduction in the number of new acquisitions, indicating potential difficulties in finding quality targets for expansion [6][7] Competitive Landscape - Ruipai's competitive advantage lies in its unique Veterinary Development Partners (VDP) model and a three-tier medical system, which have contributed to its high gross margin of 24.8% [4][5] - However, the company is heavily reliant on acquisitions, with 78% of its stores acquired, leading to integration challenges and varying service standards across locations [7][8] Future Outlook - Industry experts suggest that Ruipai must shift from an acquisition-driven growth strategy to a dual approach of internal growth and acquisitions to enhance its competitive sustainability [9][10] - The company faces financial risks, including significant goodwill and high operational costs, which could impact its profitability if not managed effectively [8][9]